Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Clinical Journal of Gastroenterology
Published in: Clinical Journal of Gastroenterology 3/2020

Open Access 01-06-2020 | Magnetic Resonance Imaging | Case Report

An elderly man with progressive focal nodular hyperplasia

Authors: Koichi Hamada, Satoshi Saitoh, Noriyuki Nishino, Daizo Fukushima, Kae Techigawara, Ryota Koyanagi, Yoshinori Horikawa, Yoshiki Shiwa, Hideo Sakuma, Fukuo Kondo

Published in: Clinical Journal of Gastroenterology | Issue 3/2020

Login to get access

Abstract

Patients with focal nodular hyperplasia (FNH) develop benign hepatocellular nodules. FNH most frequently occurs in young women. There are no reports of the onset of FNH in elderly men. We report a case of FNH in an elderly man, whose nodules increased in number and size. The patient underwent surgery for carcinoma of the left renal pelvis at 69 years of age; no liver masses were noted on yearly follow-up contrast-enhanced computed tomography (CECT). Ten years later, CECT revealed a hepatic mass, and magnetic resonance imaging suggested FNH. The nodules increased in number and size in subsequent follow-up examinations.
Literature
1.
Wang W, Chen LD, Lu MD, et al. Contrast-enhanced ultrasound features of histologically proven focal nodular hyperplasia: diagnostic performance compared with contrast-enhanced CT. Eur Radiol. 2013;23:2546–54.CrossRef
2.
Bertin C, Egels S, Wagner M, et al. Contrast-enhanced ultrasound of focal nodular hyperplasia: a matter of size. Eur Radiol. 2014;24:2561–71.CrossRef
3.
Kong WT, Wang WP, Huang BJ, et al. Contrast-enhanced ultrasound in combination with color Doppler ultrasound can improve the diagnostic performance of focal nodular hyperplasia and hepatocellular adenoma. Ultrasound Med Biol. 2015;41:944–51.CrossRef
4.
Roche V, Pigneur F, Tselikas L, et al. Differentiation of focal nodular hyperplasia from hepatocellular adenomas with low-mechanical-index contrast-enhanced sonography (CEUS): effect of size on diagnostic confidence. Eur Radiol. 2015;25:186–95.CrossRef
5.
McInnes MD, Hibbert RM, Inacio JR, et al. Focal nodular hyperplasia and hepatocellular adenoma: accuracy of gadoxetic acid-enhanced MR imaging-a systematic review. Radiology. 2015;277:927.CrossRef
6.
Guo Y, Li W, Cai W, et al. Diagnostic value of gadoxetic acid-enhanced MR imaging to distinguish HCA and its subtype from FNH: a systematic review. Int J Med Sci. 2017;14:668–74.CrossRef
7.
Busireddy KK, Ramalho M, AlObaidy M, et al. Multiple focal nodular hyperplasia: MRI features. Clin Imaging. 2018;49:89–96.CrossRef
8.
Zarghampour M, Fouladi DF, Pandey A, et al. Utility of volumetric contrast-enhanced and diffusion-weighted MRI in differentiating between common primary hypervascular liver tumors. JMRI. 2018;48:1080–90.CrossRef
9.
Luciani A, Kobeiter H, Maison P, et al. Focal nodular hyperplasia of the liver in men: is presentation the same in men and women? Gut. 2002;50:877–80.CrossRef
10.
Bartolotta TV, Taibbi A, Brancatelli G, et al. Imaging findings of hepatic focal nodular hyperplasia in men and women: are they really different? Radiol Med (Torino). 2014;119:222–30.CrossRef
11.
Maillette de Buy Wenniger L, Terpstra V, Beuers U. Focal nodular hyperplasia and hepatic adenoma: epidemiology and pathology. Dig Surg. 2010;27:24–31.CrossRef
12.
Bioulac-Sage PBC, Wanless I. Focal nodular hyperplasia and hepatocellular adenoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. 4th ed. Lyon; 2010. pp. 198–204.
13.
Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43:515–24.CrossRef
14.
Kondo F, Koshima Y, Ebara M. Nodular lesions associated with abnormal liver circulation. Intervirology. 2004;47:277–87.CrossRef
15.
Kondo F. Benign nodular hepatocellular lesions caused by abnormal hepatic circulation: etiological analysis and introduction of a new concept. J Gastroenterol Hepatol. 2001;16:1319–28.CrossRef
16.
Wells ML, Hough DM, Fidler JL, et al. Benign nodules in post-Fontan livers can show imaging features considered diagnostic for hepatocellular carcinoma. Abdom Radiol. 2017;42:2623–31.CrossRef
17.
Sugimoto K, Kondo F, Furuichi Y, et al. Focal nodular hyperplasia-like lesion of the liver with focal adenoma features associated with idiopathic portal hypertension. Hepatol Res. 2014;44:E309–E315315.CrossRef
18.
Vilgrain V, Paradis V, Van Wettere M, et al. Benign and malignant hepatocellular lesions in patients with vascular liver diseases. Abdom Radiol. 2018;43:1968–77.CrossRef
19.
Leconte I, Van Beers BE, Lacrosse M, et al. Focal nodular hyperplasia: natural course observed with CT and MRI. J Comput Assist Tomogr. 2000;24:61–6.CrossRef
20.
Kuo YH, Wang JH, Lu SN, et al. Natural course of hepatic focal nodular hyperplasia: a long-term follow-up study with sonography. JCU. 2009;37:132–7.
21.
Sadowski DC, Lee SS, Wanless IR, et al. Progressive type of focal nodular hyperplasia characterized by multiple tumors and recurrence. Hepatology. 1995;21:970–5.CrossRef
22.
Kudo M, Zheng RQ, Chung H, et al. Long-term follow-up of atypical progressive focal nodular hyperplasia increasing in size and number implicates its pathogenesis. Am J Gastroenterol. 2008;103:2153–5.CrossRef
23.
Giannitrapani L, Soresi M, La Spada E, et al. Sex hormones and risk of liver tumor. Ann N Y Acad Sci. 2006;1089:228–36.CrossRef
24.
Mamone G, Caruso S, Cortis K, et al. Complete spontaneous regression of giant focal nodular hyperplasia of the liver: magnetic resonance imaging evaluation with hepatobiliary contrast media. World J Gastroenterol. 2016;22:10461–4.CrossRef
25.
Mathieu D, Kobeiter H, Maison P, et al. Oral contraceptive use and focal nodular hyperplasia of the liver. Gastroenterology. 2000;118:560–4.CrossRef
26.
Ishak KG, Goodman ZD, Stocker JT. Benign hepatocellular tumors. In: Ishak KG, Goodman ZD, Stocker JT, editors. Tumor of the liver and intrahepatic bile ducts. Atlas of tumor pathology, 3rd series. Washington DC: Armed Forces Institute of Pathology; 1999. pp. 9–48.
Metadata
Title
An elderly man with progressive focal nodular hyperplasia
Authors
Koichi Hamada
Satoshi Saitoh
Noriyuki Nishino
Daizo Fukushima
Kae Techigawara
Ryota Koyanagi
Yoshinori Horikawa
Yoshiki Shiwa
Hideo Sakuma
Fukuo Kondo
Publication date
01-06-2020
Publisher
Springer Singapore
Published in
Clinical Journal of Gastroenterology / Issue 3/2020
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-019-01072-9

Other articles of this Issue 3/2020

Clinical Journal of Gastroenterology 3/2020 Go to the issue

Case Report

Long-term survival and renal dysfunction in a patient with recurrent colorectal cancer treated with Bevacizumab

Case Report

Distribution of lanthanum carbonate in the gastric mucosa confirmed by electron microscopy with a magnified endoscopy: a case report and literature review

Case Report

The natural progression of a fistulizing gallstone resulting in massive gastrointestinal hemorrhage and Bouveret syndrome, a rare case

Case Report

Localized biphasic malignant peritoneal mesothelioma presenting as a rectal tumor

Case Report

Gastric gastrointestinal stromal tumor with predominant cystic formation diagnosed by endoscopic ultrasound-fine needle aspiration

Case Report

A rare case of peliosis hepatis in a patient with chronic renal failure and renal cell carcinoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits